Intraductal Papillary Mucinous Neoplasm of the Pancreas; Up-to-Date
- *Corresponding Author:
- Augustin Catalin Dima, MD
Dr Carol Davila Central University Emergency Military Hospital
Bucharest, Romania, 88 Mircea Vulcanescu Street
E-mail: [email protected] yahoo.com
Received Date: July 15, 2015; Accepted Date: August 10, 2015; Published Date: August 17, 2015
Citation: Dima AC, Moldovan SC, Dima A, Ciurea M. Intraductal Papillary Mucinous Neoplasm of the Pancreas; Up-to-Date. Journal of Surgery [Jurnalul de chirurgie]. 2015; 11(3): 99-101 DOI:10.7438/1584-9341-11-3-2
Copyright: © 2015 Dima AC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The intraductal papillary mucinous neoplasm (IPMN) is a proven precursory lesion of pancreatic cancer, maybe the most important. The pancreatic cancer is a pathology associated with high rates of mortality. The IPMN develops from the epithelial ductal pancreatic cells and it expresses as cystic dilation of the main pancreatic duct and/or its branches, being part of the differential diagnosis of the cystic pancreatic masses. The identification of “invasive” and high-grade dysplasia IPMN lesions is imperiously necessary for a correct therapeutic approach; the pancreatic complementary resection being indicated in all cases with high-grade dysplasia upon the surgical margins of frozen section examinations.